Replies to post #16382 on Synaptogenix Inc (SNPX)

[rayovacAAA]

"A POST-HOC ANALYSIS"!!!!!!!!!!!!!

“Due to the baseline imbalance observed in the study, and because a clear signal of benefit could be observed in the raw data from the pre-specified Moderate Stratum, we conducted a post-hoc analysis using paired data for individual patients, with each patient as his/her own control,”

NTRP:

PLACEBO PATIENTS SCORED BETTER THAN THOSE ON OUR DRUG, SO WE WILL THROW THE PLACEBO DATA OUT AND USE "EACH PATIENT AS HIS/HER OWN CONTROL"!!!!!!!



NO WONDER NTRP HAS A $25 MILLION MC AND AGREED TO A MERGER WITH A COMPANY WHO MADE FALSE AND MISLEADING CLAIMS ABOUT THE RISK AND EFFICACY OF THEIR DRUG!!!!!!!!!!

[rayovacAAA]

$2.7 MILLION IS NOT EVEN A ROUNDING ERROR TO THE NIH GIVEN THEY ARE PROJECTED TO SPEND OVER $2.8 BILLION ON AD RESEARCH IN 2020!!!!!!!!!!!!!!

The Company is pleased to announce that it has been awarded $2.7 million from the National Institute of Health (“NIH”) to support an additional Phase 2 clinical study focused on the Moderate Stratum for which the Company saw improvement in the 203 study. Neurotrope looks forward to working with the NIH on the continuation of the Bryostatin program. The Company is planning to meet with the Food and Drug Administration to present the totality of the clinical program data for Bryostatin-1 (NTRP101-202 and NTRP101-203).